New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.

子宫内膜癌（Endometrial Cancer, EC）是发达国家最常见的妇科恶性肿瘤，其分子特征和免疫微环境的复杂性一直是研究热点。2022年《Journal for ImmunoTherapy of Cancer》上《Biomarkers of ...

A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

This €1.6 Million financing will allow MSInsight to finalize MSIcare's technological development, demonstrate its performance ...

Neoadjuvant PD-1 blockade in mismatch repair-deficient or microsatellite instability-high, locally advanced and resectable colorectal cancer: A retrospective real-world analysis. This is an ASCO ...

Elevated expression of DHX9 has been reported in multiple cancer types and it is associated with poor prognosis. In a recently published study, researchers from Accent Therapeutics Inc. evaluated ...

As a tumor-agnostic biomarker, MSI is relevant to a vast majority of cancer patients, with up to 13 million individuals worldwide potentially eligible for this diagnostic approach each year.

Total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for locoregionally advanced low rectal cancer: A phase III randomized controlled trial ...

This €1.6 Million financing will allow MSInsight to finalize MSIcare’s technological development, demonstrate its performance in various types of cancer, and initiate the regulatory clinical ...